Counterpoint Mutual Funds
ABCL icon

Counterpoint Mutual Funds’s AbCellera Biologics ABCL Stock Holding History

Counterpoint Mutual Funds’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-971,643
Closed -$7.63M – 325
2026
Q2 		$7.63M Buy
+971,643
New +$4.75M 0.75% 22
2023
Q1 		– Sell
-15,625
Closed -$158K – 330
2022
Q4 		$158K Buy
+15,625
New +$180K 0.17% 42

Other funds holding ABCL

TD Waterhouse Canada
TD Waterhouse Canada Toronto, Ontario, Canada $38.4B AUM 30.28% 1-Year Est. Return
GAA
Green Alpha Advisors Niwot, Colorado $148M AUM 98.22% 1-Year Est. Return
DWM
DKM Wealth Management Stockton, California $158M AUM 11.62% 1-Year Est. Return
IFP Advisors
IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
PP
Pacifica Partners Surrey, Canada $332M AUM 43.09% 1-Year Est. Return
CIA
Cape Investment Advisory Mcdonough, Georgia $388M AUM 17.15% 1-Year Est. Return
RE
Rydar Equities Weatherford, Texas $194M AUM 23.21% 1-Year Est. Return

Counterpoint Mutual Funds's ABCL Position: Q3 2026 in Review

Counterpoint Mutual Funds sold out of AbCellera Biologics (ABCL) in Q3 2026, closing a stake of 971,643 shares — an estimated $7.63M sold.

Counterpoint Mutual Funds first reported a position in ABCL in Q4 2022 and held it in 2 quarters. The position peaked at $7.63M in Q2 2026. 8 funds tracked by Wall St. Rank hold ABCL as of Q3 2026.

  • Counterpoint Mutual Funds reported no remaining AbCellera Biologics position as of Q3 2026 after selling out during the quarter.
  • Counterpoint Mutual Funds sold 971,643 AbCellera Biologics shares in Q3 2026, an estimated $7.63M.
  • Counterpoint Mutual Funds first reported a position in AbCellera Biologics in Q4 2022 and held it in 2 quarters.
  • Counterpoint Mutual Funds's AbCellera Biologics position peaked at $7.63M in Q2 2026.
  • 8 funds tracked by Wall St. Rank held AbCellera Biologics as of Q3 2026.

Based on Counterpoint Mutual Funds's 13F filing for Q3 2026, filed 16 Oct 2026.